Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
3.145
+0.045 (1.45%)
Jul 9, 2025, 10:07 AM - Market open
Aptevo Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
37
Market Cap
11.66M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
APVO News
- 18 days ago - Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules - Accesswire
- 19 days ago - Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers - Accesswire
- 19 days ago - Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
- 20 days ago - Aptevo More Than Doubles After Favorable Results in Leukemia Study - Market Watch
- 20 days ago - Aptevo Therapeutics Touts Data From Investigational Drug Trial For Aggressive Blood Cancer - Benzinga
- 20 days ago - Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules - Accesswire
- 21 days ago - Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML - Accesswire
- 26 days ago - Aptevo Participating in the BIO International Convention - Accesswire